Astria Therapeutics (ATXS) Net Cash Flow: 2013-2024
Historic Net Cash Flow for Astria Therapeutics (ATXS) over the last 12 years, with Dec 2024 value amounting to -$115.9 million.
- Astria Therapeutics' Net Cash Flow fell 63.73% to -$7.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$5.0 million, marking a year-over-year decrease of 364.54%. This contributed to the annual value of -$115.9 million for FY2024, which is 174.75% down from last year.
- As of FY2024, Astria Therapeutics' Net Cash Flow stood at -$115.9 million, which was down 174.75% from $155.0 million recorded in FY2023.
- In the past 5 years, Astria Therapeutics' Net Cash Flow ranged from a high of $155.0 million in FY2023 and a low of -$115.9 million during FY2024.
- Over the past 3 years, Astria Therapeutics' median Net Cash Flow value was -$65.9 million (recorded in 2022), while the average stood at -$8.9 million.
- Its Net Cash Flow has fluctuated over the past 5 years, first skyrocketed by 391.69% in 2020, then tumbled by 207.09% in 2022.
- Over the past 5 years, Astria Therapeutics' Net Cash Flow (Yearly) stood at $14.7 million in 2020, then surged by 319.61% to $61.6 million in 2021, then plummeted by 207.09% to -$65.9 million in 2022, then surged by 335.07% to $155.0 million in 2023, then crashed by 174.75% to -$115.9 million in 2024.